N/A N=355 TactiFlex Paroxysmal Atrial Fibrillation IDE Trial
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Device or Procedure-related Serious Adverse Events — 12; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=40 Clinical Trial Intelligent Biometrics for PTSD - Clinical Trial
PTSD
Primary: Post Traumatic Stress Disorder Symptom Severity - Clinician Rated — 25.71; 32.00 units on a scale
N/A N=45 The WISE Trial - Walking Improvement for SCI With Exoskeleton
Injuries, Spinal Cord
Primary: Change in Gait Speed From Baseline to 12 Weeks Using 10 Meter Walk Test (10MWT) — 0.18; 0.07; 0.03 meters/second
Phase 2 N=24 Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Melanoma · Lung Cancer
Primary: Phase 2, Overall Response — 0; 0; 0; 0 Participants
N/A N=9 Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
Malignant Melanoma · Head and Neck Cancer
Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants
N/A N=32 Yoga and Mantram for Chronic Pain and PTSD
Post-Traumatic Stress Disorder · Chronic Low Back Pain · Chronic Neck Pain
Primary: Roland-Morris Disability Questionnaire (RMDQ) — 13.6; 14.3 score on a scale
Phase 2 N=49 The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application) — 6.72; -3.37 scores on a scale
N/A N=183 Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Phase 2 N=3 Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Myelofibrosis
Primary: Number of Patients That Achieve Stable Disease or Clinical Improvement — 3; 4; 1; 3 Participants
Phase 3 N=505 Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Urothelial Carcinoma
Primary: Progression-free Survival (PFS) — 4.5; 4.0 Months — p=0.4107
N/A N=291 The Helping Older People Engage Project: Improving Social Well-Being in Later Life
Loneliness · Quality of Life
Primary: Loneliness — 44.36; 44.10 units on a scale — p=.896
Phase 2 N=22 A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Corneal Endothelial Dystrophy · Fuchs Endothelial Corneal Dystrophy · Pseudophakic Bullous Keratopathy
Primary: DLTs/ Adverse Reactions — 0; 0; 0; 0 Participants
Phase 1 N=51 A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Breast Cancer · Prostate Cancer · Ovarian Cancer
Primary: Percentage of Participants With Adverse Events — 100; 100; 100; 100 percentage of participants
N/A N=40 Umbilical Cord Blood Transplant for Congenital Pediatric Disorders
Congenital Pediatric Disorders
Primary: Overall Survival at 100 Days After Umbilical Cord Blood Transplant in Pediatric Patients. — 0.947 probability of overall survival
Phase 1 N=477 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Solid Tumor
Primary: Overall Response Rate (ORR) — 4.3; 20.0; 0.0; 30.4 Percentage of Participants